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Adaptive immune resistance ablates effective anti-tumor immune responses. In a recent issue of Nature,
Victor and colleagues describe that anti-PD-L1 combats adaptive immune resistance upon localized
radiation plus anti-CTLA-4 therapy. The superior activity of radiation and dual immune checkpoint blockade
is mediated by non-redundant immune mechanisms in cancer.Combinations of two or more immuno-
therapies with additive or synergistic
benefit in preclinical models (Uno et al.,
2006) have set the framework for combi-
nation successes in the clinic (Wolchok
et al., 2013). With the recent success of
immune checkpoint inhibitors and other
immunomodulators, there has been re-
newed interest in evaluating the combina-
tion of such agents with radiation therapy
(RT) in clinical trials (Verbrugge et al.,
2012; Formenti and Demaria, 2013). The
biologic premise behind such a strategy
is that the tumor-antigen release and
change in the tumor microenvironment
achieved by localized RT will promote
specific tumor targeting by the adap-
tive immune system, which can be
augmented further by systemic immune-
stimulating agents (Tang et al., 2014). In
this manner, clinicians hope to induce
a phenomenon known as the abscopal
effect, whereby localized RT results in im-
mune-mediated tumor regression in dis-
ease sites well outside of the radiation
field. RT also induces DNA damage and
tumor cell death by promoting tumor-cell
expression of Fas and MHC class I. Dying
tumor cells release not only tumor anti-
gens but also ATP and danger signals
such as HMGB1 and calreticulin. RT also
has some potentially deleterious effects
by increasing the tumor cell expression
of PD-L1, secretion of TGFb, and induc-
tion of Treg. A small pilot phase I/II study
in prostate cancer (Slovin et al., 2013)
and case reports in melanoma (Postow
et al., 2012; Hiniker et al., 2012; Golden
et al., 2013) combining RT with ipilimu-mab show the possible clinical activity of
this approach.
Now, Victor et al. (2015) report a phase I
clinical trial of 22 patients with advanced
melanoma treated with RT and anti-
CTLA-4. In the trial, a single lesion was
irradiated with hypofractionated stereo-
tactic body radiation (6–8 Gy delivered
over two or three fractions), followed by
four cycles of ipilimumab beginning 3–
5days after the last fraction of RT. Assess-
ment of unirradiated lesions usingRECIST
criteria demonstrated 18% patients had
a partial response as the best response,
18% had stable disease, and 64% had
progressive disease. So, although partial
responses were observed, like mono-
therapy with anti-CTLA-4, the majority of
the patients did not respond.
The authors then describe the use of
the B16-F10 melanoma mouse model,
where RT plus anti-CTLA-4 was more
effective than either treatment alone, pro-
moting the regression of both irradiated
and unirradiated tumors (Victor et al.,
2015). RT given before, or concurrently
with, anti-CTLA-4 yielded similar results.
Complete responses in these combina-
tion-treated mice were CD8+ T cell-
dependent, and memory to rechallenge
was demonstrated. However, not all
mice responded, and melanoma cell
lines from relapsing mice were derived.
In these cell lines, resistance to the com-
bination was confirmed, but the lesions
were not RT resistant. Random forest ma-
chine learning analysis for sub-types of
TIL isolated from the resistant melanomas
demonstrated that the top predictor forCancer Celresistance was the CD8+CD44+ to Treg
ratio, which failed to increase after RT
plus anti-CTLA-4 (as it did in sensitive
tumors).
Transcriptomic profiling revealed that
PD-L1 was among the top 0.2% of
upregulated genes in melanoma (RT plus
anti-CTLA-4 resistance signature). Ge-
netic elimination of PD-L1 on the ther-
apy-resistant Res499 melanoma cells by
CRISPR dramatically restored response
to RT plus anti-CTLA-4 (0% to 60% sur-
vival), suggesting upregulation of PD-L1
was one major mechanism, but not
the only mechanism of resistance to RT
plus anti-CTLA-4. In the original parental
B16-F10, RT plus anti-CTLA-4 increased
the proportion of PD-1+Eomes+ CD8
T cells and the proportion that were
Ki67+ and granzyme (Grz) B+. But in the
resistant sublines, the Ki67+GrzB+ CD8
T cells were not increased. The frequency
of PD-1+CD8+ T cells that were Eomes+
was a striking modifier of the likelihood
of a complete response (CR), because
nearly all the CRs occurred when the
frequency of Ki67+GrzB+ in PD-1+CD8+
was high, but the relative size of the PD-
1+Eomes+-exhausted population was
small. Critically, adding anti-PD-L1
improved responses to the naive B16-
F10 and resistant sublines after RT plus
anti-CTLA-4. Similar results were ob-
tained in the mouse TSA mammary tumor
and a mouse pancreatic tumor model.
Random forest modeling showed that
anti-CTLA-4 predominantly caused a
decrease in Treg cells, anti-PD-L1
strongly increased CD8 TIL frequency,l 27, April 13, 2015 ª2015 Elsevier Inc. 437
Figure 1. Schematic Model for Non-redundant Mechanisms of RT/Anti-CTLA-4/Anti-PD-L1
Therapy to Combat Immune Resistance in Melanoma
Adapted from Victor et al. (2015) Extended Data Figure 6.
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Treg ratio. RT only caused a modest
increase in CD8 TILs; however, TCR
sequencing revealed that there was an
increased diversity of TCR clonotypes,
which was also observed with RT plus
anti-CTLA-4. This effect was also seen in
the spleen and peripheral blood. Some
clones reached 20% post-treatment
in the blood with triple treatment. By
contrast, peripheral T cell expansion was
modest with RT and anti-CTLA-4 alone.
So the concept gleaned from the mouse
studies was that favorable immune
changes in TILs after immune check-
point blockade promoted their peripheral
clonal expansion. When combined with
increased TCR repertoire diversity af-
forded by RT, selection and oligoclonal
peripheral expansion of clones with
distinct TCR traits were favored (Figure 1).
From the clinical trial of RT + ipilimu-
mab, 12 patients had pre-treatment tumor
biopsies, and pre- and post-treatment
blood was available on 10 patients.
From these low numbers, it was revealed
that PD-L1lo intensity on melanoma cells
was associated with re-invigoration of
PD-1+Eomes+ CD8+ T cells after RT plus
anti-CTLA-4, while PD-L1hi status was
associated with persistent exhaustion of
the CD8+T cells. PD-L1hi on melanoma
biopsies collected from therapy-resistant
patients is potentially reflecting the438 Cancer Cell 27, April 13, 2015 ª2015 Elsfailure of CTL anti-tumor cytotoxicity,
consistent with the lower frequencies
of Ki67+GrzB+PD1+CD8+ T cells. As dis-
cussed above, it is also worth empha-
sizing that a proportion of the mice with
PD-L1 knockout Res499 cells still suc-
cumbed to disease after RT plus anti-
CTLA-4 treatment, suggesting a role for
non-tumor PD-L1 in promoting resistance
to RT/anti-CTLA-4. Intriguingly, despite
other recent reports (Herbst et al., 2014)
PD-L1 status on the macrophages was
neither associated with reinvigoration
nor independently predictive of progres-
sion-free survival. Although there may be
activation of other T cell checkpoint path-
ways, the hierarchy of PD-L1 expression
on tumor cells and non-tumor cells in
driving T cell exhaustion warrants further
study in larger patient cohorts. Nonethe-
less, the mechanism of radiation to
diversify TCR clonotypes remains to be
discerned.
Radiotherapy is a major component of
cancer treatment, with over 50% of can-
cer patients receiving radiation during
the course of their disease. Radiation is
used for both palliation of local symptoms
and curative therapy in some malig-
nancies, like lung, prostate, or head and
neck cancer. However, although radiation
offers clear benefits in terms of both local
control and survival, disease recurrence
outside the radiation field remains all tooevier Inc.common, and most patients eventually
die from progressive metastatic disease.
A considerable amount of work remains
to be done to create successful com-
binations of immunotherapeutics and
radiation, which includes identifying the
optimal radiation dose, fractionation, and
sequence for use in combination with im-
mune checkpoint inhibitors.ACKNOWLEDGMENTS
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